KGbio

Ownership

Private

Employees

~100

Therapeutic Areas

Oncology

Stage

Commercial

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Fc-fusion proteinsantibodiesbispecificsADCscell therapiestherapeutic vaccines

KGbio General Information

No specific clinical results provided in search results

Contact Information

Website

https://www.kg-biologics.com/

Primary Industry

Biotech

Corporate Office

,
Taiwan

Drug Pipeline

efepoetin alfa

Commercial

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to KGbio's pipeline data

Key Partnerships

FIRDI, NPUST, Taiwan Ministry of Economic Affairs

Need more data on over 80,000 life science companies, including over 1200 biotechs?

KGbio Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view KGbio's complete valuation and funding history, request access »

KGbio Financial Metrics